Recent insights into the functions of the retinoblastoma susceptibility gene product

Cancer Investigation

Volumn 15, Issue 3, 1997, Pages 243-254

  Kaelin Jr , William G ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; GENE PRODUCT;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; CANCER GROWTH; CELL CYCLE S PHASE; CHROMOSOME 13; GENE FUNCTION; GENE LOCATION; GERM LINE; GROWTH REGULATION; PRIORITY JOURNAL; RETINOBLASTOMA; TARGET CELL; TUMOR SUPPRESSOR GENE;

EID: 1842289794     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039722     Document Type: Article

References (183)

1. Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823, 1971.
2. Lee W-H, Bookstein R, Hong F, et al: Human retinoblastoma susceptibility gene: Cloning, identification, and sequence. Science 235:1394-1399, 1987.
3. Friend SH, Bernards R, Rogelj S, et al: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646, 1986.
4. Fung Y-KT, Murphree AL, T'Ang A, et al: Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:1657-1661, 1987.
5. Hong FD, Huang H, To H, et al: Structure of the human retinoblasloma gene. Proc Natl Acad Sci USA 86:5502-5506, 1989.
6. T'Ang A, Wu K, Hashimoto T, et al: Genomic organization of the human retinoblastoma gene. Oncogene 4:401-407, 1989.
7. McGee TL, Yandell DW, Dryja TP: Structure and partial genomic sequence of the human retinoblastoma susceptibility gene. Gene 80:119-128, 1989.
8. Eng C, Li F, Abramson DH, et al: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121-1128, 1993.
9. Gallie B; Retinoblastoma gene mutations in human cancer. N Engl J Med 330:786-787, 1994.
10. Lee W-H, Shew J-Y, Hong FD, et al: The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 329:642-645, 1987.
11. Harbour JW, Lai S, Whang-Peng J, et al: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353-356, 1988.
12. Horowitz JM, Park S, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775-2779, 1990.
13. Kaye FJ, Kratzke RA, Gerster JL, et al: A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc Natl Acad Sci USA 87:6922-6926, 1990.
14. Kratzke RA, Otterson GA, Hogg A, et al: Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. Oncogene 9:1321-1326, 1994.
15. Friend SH, Horowitz JM, Gerber MR, et al: Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: Organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 84:9059-9063, 1987.
16. Horowitz JM, Yandell DW, Park S, et al: Point mutational inactivation of the retinoblastoma antioncogene. Science 243:937-940, 1989.
17. T'Ang A, Varley JM, Chakraborty S, et al: Structural rearrangement of the retinoblastoma gene in human breast cancer. Science 242:263-266, 1988.
18. Varley JM, Armour J, Swallow JE, et al: The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene 4:725-729, 1989.
19. Bookstein R, Shew J, Chen P, et al: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715, 1990.
20. Hensel CH, Hsieh C-L, Gazdar AF, et al: Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res 30:3067-3072, 1990.
21. Lee EY-HP, to H, Shew J-Y, et al: Inactivation of the retinoblas toma susceptibility gene in human breast cancers. Science 241:218-221, 1988.
22. Reissmann PT, Simon MA, Lee W-H, et al: Studies of the retinoblastoma gene in human sarcomas. Oncogene 4:839-843, 1989.
23. Shew J, Chen P, Bookstein R, et al: Deletion of a splice donor site ablates expression of the following exon and produces an unphosphorylated RB protein unable to bind SV40 T antigen. Cell Growth Diff 1:17-25, 1990.
24. Shew J, Lin BT, Chen P, et al: C-terminal truncation of the retinoblastoma gene product leads to functional inactivation. Proc Natl Acad Sci USA 87:6-10, 1990.
25. Toguchida J, Ishizaki K, Sasaki MS, et al: Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature 338:156-158, 1989.
26. Weichselbaum RR, Beckett M, Diamond A: Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. Proc Natl Acad Sci USA 85:2106-2109, 1988.
27. Scheffner M, Munger K, Byrne JC, et al: The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88:5523-5527, 1991.
28. Takahashi R, Hashimoto T, Xu H-J, et al: The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci USA 88:5257-5261, 1991.
29. Huang H-JS, Yee J-K, Shew J-Y, et al: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563-1566, 1988.
30. Sumegi J, Uzvolgyi E, Klein G: Expression of the RB gene under the control of the MuLV-LTR suppresses tumorigenicity of WERI-Rb-27 retinoblastoma cells in immunodefective mice. Cell Growth Diff 1:247-250, 1990.
31. Qin X-Q, Chittenden T, Livingston DM, et al: Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev 6:953-964, 1992.
32. Qin X-Q, Livingston DM, Ewen M, et al: The transcription factor E2F1 is a downstream target of RB action. Mol Biol Cell 15:742-755, 1995.
33. Qian Y, Luckey C, Horton L, et al: Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol Cell Biol 12:5363-5372, 1992.
34. Hinds PW, Mittnacht S, Dulic V, et al: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006, 1992.
35. Whyte P, Buchkovich KJ, Horowitz JM, et al: Association between an oncogene and an antioncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334:124-129, 1988.
36. Dyson N, Howley PM, Munger K, et al: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937, 1989.
37. DeCaprio JA, Ludlow JW, Figge J, et al: SV40 large T antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283, 1988.
38. Dyson N, Bernards R, Friend SH, et al: Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J Virol 64:1353-1356, 1990.
39. Figge J, Webster T, Smith TF, et al: Prediction of similar transforming regions in simian virus 40 large T, adenovirus E1A, and myc oncoproteins. J Virol 62:1814-1818, 1988.
40. Figge J, Smith TF: Cell-division sequence motif. Nature 334:109, 1988.
41. Nevins JR: E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429, 1992.
42. DeCaprio JA, Ludlow JW, Lynch D, et al: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58:1085-1095, 1989.
43. DeCaprio JA, Furukawa Y, Ajchenbaum F, et al: The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci USA 89:1795-1798, 1992.
44. Chen P, Scully P, Shew J, et al: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58:1193-1198, 1989.
45. Mihara K, Cao X, Yen A, et al: Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246:1300-1303, 1989.
46. Buchkovich K, Duffy LA, Harlow E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58:1097-1105, 1989.
47. Ludlow JW, DeCaprio JA, Huang C, et al: SV40 Large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell 56:57-65, 1989.
48. Dorée M, Galas S: The cyclin dependent protein kinases and the control of cell division. FASEB J 8:1114-1121, 1994.
49. Lee MG, Nurse P: Complementation used Io clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 327:31-35, 1987.
50. Ewen ME, Sluss HK, Sherr CJ, et al: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497, 1993.
51. Dowdy SF, Hinds PW, Louie K, et al: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499-511, 1993.
52. Kato J-Y, Matsushime H, Hiebert SW, et al: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase cdk4. Genes Dev 7:331-342, 1993.
53. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995.
54. Ludlow JW, Shon J, Pipas JM, et al: The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from Sv40 large T. Cell 60:387-396, 1990.
55. Ludlow JW, Glendening CL, Livingston DM, et al: Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol 13:367-372, 1993.
56. Hunter T, Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994.
57. Elledge SJ, Harper JW: Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6:847-852, 1994.
58. Guan K-L, Jenkins CW, Li Y, et al: Growth suppression by p18, a p16 INK4/MTS1 and p14 INK4B/MTS1-related CDK6 inhibitor, correlates wilh wild-type pRb function. Genes Dev 8:2939-2952, 1994.
59. Serrano M, Gomez-Lahoz E, DePinho RA, et al: Inhibition of ras-induced proliferation and cellular transformation by p161NK4. Science 267:249-252, 1995.
60. EI-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
61. Harper JW, Adami GR, Wei N, et al: The p21 Cdk-interacting protein CIP1 is a potent inhibitor of G1 cyclin-dependent kinascs. Cell 75:805-816, 1993.
62. Xiong Y, Hannon GJ, Zhang H, et al: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
63. Kuerbitz SJ, Plunkett BS, Walsh WV, et al: Wild type p53 is a cells cycle chechpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
64. Ewen M, Oliver C, Sluss H, et al: p53-Dependent repression of CDK4 translation in TGF-β-induced G1 cell-cycle arrest. Genes Dev 9:204-217, 1995.
65. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261, 1994.
66. Polyaak K, Lee M-H, Erdjument-Bromage H, et al: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994.
67. Kaelin WG, Ewen ME, Livingston DM: Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-finding domain in the retinoblastoma gene product. Mol Cell Biol 10:3761-3769, 1990.
68. Huang S, Wang N, Tseng BY, et al: Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. EMBO J 9:1815-1822, 1990.
69. Hu Q, Dyson N, Harlow E: The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J 9:1147-1155, 1990.
70. Kaelin WG, Pallas DC, DeCaprio JA, et al: Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell 64:521-532, 1991.
71. Huang S, Lee W-H, Lee Y-HP: A cellular protein that competes with SV40 T antigen for binding the retinoblastoma gene product. Nature 350:160-162, 1991.
72. Chittenden T, Livingston DM, Kaelin WG: The T/E1A-binding domain of the retinoblastom product can interact selectively with a sequence-specific DNA-binding protein. Cell 65:1073-1082, 1991.
73. Bandara LR, La Thangue NB: Adenovirus E1A prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature 351:494-497, 1991.
74. Bagchi S, Weinmann R, Raychaudhuri P: The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell 65:1063-1072, 1991.
75. Chellappan SP, Hiebert S, Mudryj M, et al: The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053-1061, 1991.
76. Kovesdi I, Reichel R, Nevins JR: Identification of a cellular transcription factor involved in E1A trans-activation. Cell 45:219-228, 1986.
77. LaThangue NB, Rigby PWJ: An adenovirus E1A-like transcription factor is regulated during the differentiation of murine embryonal carcinoma stem cells. Cell 49:507-513, 1987.
78. Farnham PJ, Slansky JE, Kollmar R: The role of E2F in the mammalian cell cycle. Biochim Biophys Acta 1155:125-131, 1993.
79. Goodrich DW, Wang NP, Qian Y-W, et al: The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67:293-302, 1991.
80. Hiebert SW: Regions of the relinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-Mediated growth suppression. Mol Cell Biod 13:3384-3391, 1993.
81. Huang S, Shin E, Sheppard K-A, et al: The retinoblastoma protein region required for interaction with the E2F transcription factor includes the T/E1A binding and carboxyl-terminal sequences. DNA Cell Biol 7:539-548, 1992.
82. Welch PJ, Wang JYJ: C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75:779-790, 1993.
83. Kim S-J, Wagner S, Liu F, et al: Retinoblastoma gene product activates expression of the human TGF-β2 gene through transcription factor ATF-2. Nature 358:331-334, 1991
84. Wang C-Y, Petrynaik B, Thompson CB, et al: Regulation of an ETS-related transcription factor, E1f-1 binding to the retinoblastoma protein. Science 260:1330-1335, 1993.
85. Hagemeier C, Bannister AJ, Cook A, et al: The activation domain of transcription factor PU. 1 binds the retinoblastoma (RB) protein and the transcription factor TFIID in vitro: RB shows sequence similarity to TFIID and TFIIB. Proc Natl Acad Sci USA 90:1580-1584, 1993.
86. Shan B, Zhu X, Chen P-L, et al: Molecular cloning of cellular genes encoding retinoblasloma-associated proteins: identification of a gene with properties of the transcription factor E2F. Mol Cell Biol 12:5620-5631, 1992.
87. Gu W, Schneider JW, Condorelli G, et al: Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72:309-324, 1993.
88. Cavanaugh AH, Hempel WM, Taylor LJ, et al: Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 374:177-180, 1995.
89. Kaelin WG, Krek W, Sellers WR, et al: Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70:351-364, 1992.
90. Helin K, Lees JA, Vidai M, et al: A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70:337-350, 1992.
91. Flemington EK, Speck SH, Kaelin WG: E2F-1 mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 90:6914-6918, 1993.
92. Helin K, Harlow E, Fattaey A: Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma gene. Mol Cell Biol 13:6501-6508, 1993.
93. Lees JA, Saito M, Vidai M, et al: The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 13:7813-7825, 1993.
94. Ivey-Hoyle M, Conroy R, Huber HE, et al: Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F. Mol Cell Biol 13:7802-7812, 1993.
95. Beijersbergen RL, Kerkhoven RM, Zhu L, et al: E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev 8:2680-2690, 1994.
96. Ginsberg D, Vairo G, Chittenden T, et al: E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev 8:2665-2679, 1994.
97. Sardet C, Vidai M, Cobrinik D, et al: E2F-4 and E2F-5, two novel members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci USA 92:2403-2407, 1995.
98. Krek W, Livingston DM, Shirodkar S: Binding to DNA and retinoblastoma gene product promoted by complex formation of different E2F family members. Science 262:1557-60, 1993.
99. Helin K, Wu C-L, Fattaey AR, et al: Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative transactivation. Genes Dev 7:1850-1861, 1993.
100. Huber HE, Edwards G, Goodhart PJ, et al: Transcription factor E2F binds DNA as a heterodimer. Proc Natl Acad Sci USA 90:3525-3529, 1993.
101. Girling R, Partridge JF, Bandara LR, et al: A new component of the transcription factor DRTF1/E2F1. Nature 362:83-87, 1993.
102. Wu C-L, Zukerberg LR, Ngwu C, et al: In vivo association of E2F and DP family proteins. Mol Cell Biol 15:2536-1546, 1995.
103. La Thangue NB: DRTF1/E2F1:An expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem Sci 19:108-114, 1994.
104. Zhang Y, Chellappan SP: Cloning and characterization of human DP2, a novel dimerization partner of E2F. Oncogene 10:2085-2093, 1995.
105. Jooss K, Lam EW, Bybee A, et al: Proto-oncogenic properties of the DP family of proteins. Oncogene 10:1529-1536, 1995.
106. Vairo G, Livingston DM, Ginsberg D: Functional interaction between E2F4 and p130: Evidence for distinct mechanisms underlying growth suppression by different Rb family members. Genes Dev Genes Dev 9:869-881, 1995.
107. Ewen ME, Xing Y, Lawrence JB, et al: Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 66:1155-1164, 1991.
108. Hannon GJ, Demetrick D, Beach D: Isolation of the Rb-related p130 through its interactions with CDK2 and cyclins. Genes Dev 7:2378-2391, 1993.
109. Cobrinik D, Whyte P, Peeper DS, et al: Cell cycle-specific association of E2F with the p130. E1A-binding protein. Genes Dev 7:2392-2404, 1993.
110. Schwarz JK, Devoto SH, Smith EJ, et al: Interactions of the p 107 and Rb proteins with E2F during the cell proliferation response. EMBO J 12:1013-1020, 1993.
111. Smith EJ, Nevins JR: The Rb related p107 protein can suppress E2F function Independently of binding to cyclin A/cdk2. Mol Cell Biol 15:338-344, 1995.
112. Zamanian M, La Thangue NB: Transcriptional repression by the RB-related protein p107. Mol Biol Cell 4:389-396, 1993.
113. Zhu L, van der Heuvel S, Helin K, et al: Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 7:1111-1125, 1993.
114. Claudio PP, Howard CM, Baldi A, et al: p130/pRb2 has growth suppression properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 54:5556-5560, 1994.
115. Lam EW-F, La Thangue NB: DP and E2F proteins: Coordinating trranscription with cell cycle progression. Curr Opin Cell Biol 6:859-866, 1994.
116. Shirodkar S, Ewen M, DeCaprio JA, et al: The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 68:157-166, 1992.
117. Jacks T, Fazeli A, Schmitt EM, et al: Effects of an Rb mutation in the mouse. Nature 359:295-300, 1992.
118. Clarke AR, Maandag ER, van Roon M, et al: Requirement for a functional Rb-1 gene in murine development. Nature 359:328-330, 1992.
119. Lee EY-HP, Chang C-Y, Hu N, et al: Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294, 1992.
120. Johnson DG, Schwarz JK,Cress WD, et al: Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365:349-352, 1993.
121. Qin XQ, Livingston DM, Kaelin WG, et al: Deregulated E2F1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 91:10918-10922, 1994.
122. Shan B, Lee W-H: Deregulated expression of E2F-1 induces Sphase entry and leads to apoptosis. Mol Cell Biol 14:8166-8173, 1994.
123. Singh P, Wong S, Hong W: Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 13:3329-3338, 1994.
124. Xu G, Livingston D, Krek W: Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci USA 92:1357-1361, 1995.
125. Johnson D, Cress W, Jakoi L, et al: Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 91:12823-12827, 1994.
126. Weintraub SJ, Prater CA, Dean DC: Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358:259-261, 1992.
127. Neuman E, Flemington EK, Sellers WR, et al: Transcription of the E2F1 gene is rendered cell-cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol 14:6607-6615, 1994.
128. Johnson DG, Ohtani K,Nevins JR: Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 8:1514-1525, 1994.
129. Hsiao K-M, McMahon SL, Farnham P: Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev 8:1526-1537, 1994.
130. Lam EW-F, Watson RJ: An E2F-binding site mediates cell-cycle regulated repression of mouse B-Myb transcription. EMBO 12:2705-2713, 1993.
131. Porcu P, Grana X, Li S, et al: An E2F binding sequence negatively regulates the response of the insulin-like growth factor 1 (IGF-I) promoter to simian virus 40T antigen and to serum Oncogene 9:2125-2134, 1994.
132. Huber HE, Goodhart PJ, Huang PS: Retinoblastoma protein reverses DNA bending by transcription factor E2F. J Biol Chem 9:6999-7005, 1994.
133. Weintraub SJ, Chow KNB, Luo RX, et al: Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375:812-815, 1995.
134. Adnane J, Shao Z, Robbins PD: The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter. J Biol Chem 270:8837-8843, 1995.
135. Sellers WR, Rodgers J, Kaelin WG: A potent transrepression domain in the retinoblastoma protein induces a cell-cycle arrest when bound to E2F sites. Proc Natl Acad Sci USA 92:11544-11548, 1995.
136. Breinner R, Cohen BL, Sopta M, et al: Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 15(6):3256-3265, 1995.
137. Shao Z, Ruppert S, Robbins PD: The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250. Proc Natl Acad Sci USA 92:3115-3119, 1995.
138. Buckley M, Sweeney K, Hamilton J, et al: Expression and amplification ot cyclin genes in human breast cancer. Oncogene 8:2127-2133, 1993.
139. Gillet C, Fantl V, Smith R, et al: Amplification and overexprcssion of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817, 1994.
140. Hunter T, Pines J: Cyclins and cancer. Cell 66:1071-1074, 1991.
141. Jiang W, Zhang Y-J, Kahn SM, et al: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 90:9026-9030, 1993.
142. Keyomarsi K, Pardee A: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90:1112-1116, 1993.
143. Keyomarsi K, O'Leary N, Molnar G, et al: Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54:380-385, 1994.
144. Leach FS, Elledge SJ, Sherr CJ, et al: Amplification of cyclin genes in cdorectal carcinomas. Cancer Res 53:1986-1989, 1993.
145. Motokura T, Bloom T, Kim HG, et al: A novel cyclin encoded by a bc 11-linked candidate oncogene. Nature 350:512-515, 1991.
146. Motokura T, Arnold A: Cyclin D and oncogensis. Curr Opin Genet Dev 3:5-10, 1993.
147. Schauer I, Siriwardana S, Langan T, et al: Cyclin D1 overexpression vs. retinoblastoma inactivation: Implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA 91:7827-7831, 1994.
148. Bartkova J, Lukas J, Muller H, et al: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353-361, 1994.
149. Musgrove E, Lee C, Buckley M, et al: Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 91:8022-8026, 1994.
150. Tam S, Theodoras AM, Shay JW, et al: Different expression and regulation of cyclin D1 in normal and tumor human cells: Association with cdk4 is required for cyclin D1 function in G1 progression. Oncogene 9:2663-2674, 1994.
151. Shapiro GI, Edwards CD, Kobzik L, et al: Reciprocal Rb inactivation and p16 expression in human lung carcinoma. Cancer Res 55:505-509, 1995.
152. Wang T, Cardiff R, Zukerberg L, et al: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 trangenic mice. Nature 369:669-671, 1994.
153. Lovec H, Sewing A, Lucibello FC, et al: Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: Link between cell cycle control and malignant transformation. Oncogene 9:323-326, 1994.
154. Hinds PW, Dowdy SF, Eaton EN, et al: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91:709-713, 1994.
155. Lukas J, Muller H, Bartkova J, et al: DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in Gl. J Cell Biol 125:625-638, 1994.
156. Khatib ZA, Matsushime H, Valentine M, et al: Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53:5535-5541, 1993.
157. He J, Alien JR, Collins VP, et al: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletions in glioma cell lines. Cancer Res 54:5804-5807, 1994.
158. Cairns P, Mao L, Merlo A, et al: Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 265:415-417, 1994.
159. 1NK4 protein is restricted to the subset of lung cancer lines that retans wildtype RB. Oncogene 9:3375-3378, 1994.
160. INK4 in human cancer. Proc Natl Acad Sci USA 91:11045-11049, 1994.
161. Mori T, Miura K, Aoki T, et al: Frequent Somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397, 1994.
162. Spruck I CH, Gonzalez-Zulueta M, Shibata A, et al: p16 gene in uncultured tumours. Nature 370:183-184, 1994.
163. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:22-26, 1994.
164. Hussussian C, Struewing J, Goldstein A, et al: Germline p16 mutations in familial melanoma. Nature Genet 8:15-21, 1994.
165. Caldas C, Hahn S, da Costa L, et al: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:27-32, 1994.
166. Okamoto A, Demetrick D, Spillare E, et al: Mutations and altered expression of p16. Proc Natl Acad Sci USA 91:11045-11049, 1994.
167. Wu X, Levine AJ: p53 and E2F1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91:3602-3606, 1994.
168. Jiang D, Srinivasan A, Lozano G, et al: SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 8:2805-2812, 1993.
169. Segawa K, Minowa A, Sugaswa K, et al: Abrogation of p53-mediated transactivation by SV40 large T antigen. Oncogene 8:543-548, 1993.
170. Bargonetti J, Reynisdottir I, Friedman PN, et al: Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 6:1886-1898, 1992.
171. Mietz JA, Unger T, Huibregtse JM, et al: The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11:5013-5020, 1992.
172. Yew PR, Berk AJ: Inhibition of p53 transactivation required for transformation by adenovirus early E1B protein. Nature 357:82-85, 1992.
173. Hoppe-Seyler F, Butz K: Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. Mol Cell Biol 67:3111-3117, 1993.
174. Scheffner M, Werness BA, Huibregtse JM, et al: The E6 oncoprotein encoded by human papillomaviruses types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136, 1990.
175. Band V, Dalal S, Delmolino L, et al: Enhanced degradation of p53 protein in HPV-E6 and BPV-1 E6 immortalized human mammary epithelial cells. EMBO J 12:1847-1852, 1993.
176. D'Amico D, Carbone D, Mitsudomi T, et al: High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7:339-346, 1992.
177. Sameshima Y, Matsuno Y, Hirohashi S, et al: Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene 7:451-457, 1992.
178. Wang NP, To H, Lee W-H, et al: Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 8:279-88, 1993.
179. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990.
180. Sidransky D, Von Eschenbach A, Tsai YC, et al: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-709, 1991.
181. Diller L, Kassel J, Nelson C, et al: p53 functions as a cell cycle control protein in osteosarcoma. Mol Cell Biol 10:5772-5781, 1990.
182. Oliner JD, Kinzler KW, Meltzer PS, et al: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83, 1992.
183. Chabner BA, Myers CE: Clinical pharmacology of cancer chemotherapy. In: Cancer-Principles and Practice of Oncology, 2nd ed, edited by VT DeVita, S Hellman, SA Rosenberg, Philadelphia, JB Lippincott, 1985, pp 287-328.